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Recurrence of primary sclerosing cholangitis after liver
transplantation – A model for pathogenesis?To the Editor:
We appreciate the important comment from Cholong-
itas et al. regarding our recently published article [1]
which discusses the pathogenesis of primary sclerosing
cholangitis (PSC). The comment points out that the iden-
tiﬁcation of risk factors for the recurrence of PSC after
liver transplantation (OLT) may help to understand
pathogenetic mechanisms of this enigmatic disease.
However, the issue of recurrent PSC (rPSC) following
OLT has always been controversial, because there are a
number of possible pathogenetic mechanisms resulting
in a phenotype of sclerosing cholangitis in the liver allo-
graft that resemble PSC [2]. These include chronic duc-
topenic rejection as well as biliary complications such as
anastomotic or non-anastomotic strictures. The latter
can be caused by hepatic artery thrombosis or stenosis,
but are also frequently seen without an obvious im-
paired arterial perfusion, and have therefore been desig-
nated ischemic-type biliary lesions (ITBL) [3]. Several
retrospective studies have found a greater frequency of
biliary strictures in patients who were transplanted for
PSC in comparison to patients receiving a liver trans-
plantation for other end-stage liver diseases [2]. It can
be assumed that these additional bile duct changes in
the allograft following OLT for PSC are due to the
recurrence of the disease. Thus, in cases of a typical
cholangiographic or histological picture following
OLT for PSC, rPSC should be diagnosed only after
the exclusion of accepted causes of sclerosing cholangitis
(which include hepatic artery thrombosis/stenosis, ABO
incompatibility, and chronic ductopenic rejection).
While anastomotic strictures alone are clearly related
to the transplantation procedure itself, the diﬀerentia-
tion between ITBL and rPSC remains diﬃcult. The
widely accepted criteria for PSC recurrence published
by the Mayo group [2] assume that – unless otherwise
explainable – biliary strictures in the cholangiogram,
or a ﬁbrous cholangitis detected in a liver biopsy speci-
men after more than 90 days following OLT for PSC are
deemed to represent rPSC. However, this 90 day rule is
questionable since a considerable number of ITBL are0168-8278/$34.00  2008 Published by Elsevier B.V. on behalf of the Europ
doi:10.1016/j.jhep.2008.08.002diagnosed more than 3 months after OLT; according
to one study [4] 40% of intrahepatic strictures were seen
more than 6 months after OLT.
In the accurate study of Cholongitas et al. [5] strict
inclusion and exclusion criteria for rPSC as deﬁnded
by the Mayo Clinic were used, based on detailed clinical
data, protocol liver biopsies and radiological ﬁndings, in
order to identify patients with rPSC. With this best pos-
sible approach to identify patients with rPSC they found
recurrence of PSC only in patients with active ulcerative
colitis (UC) after OLT. These ﬁndings are consistent
with the fascinating hypothesis of an enterohepatic cir-
culation of lymphocytes generated in the gut as a con-
cept for the pathogenesis of PSC. However these
results are based on only 53 patients and – as the
authors mentioned – previous studies including one
meta-analysis [6] did not ﬁnd a signiﬁcant inﬂuence of
UC on rPSC. In terms of methodology the study of
Cholongitas et al. [5] certainly represents one of the best
approaches to identifying risk factors for rPSC. Pro-
spective studies of the same quality level are needed to
verify these results.
In summary, in view of the diﬃculties to distinguish
rPSC from other biliary changes after OLT, especially
ITBL, the results of studies on the recurrence of PSC
should generally be considered with a degree of caution.
In the situation of rPSC we are dealing with the allograft
as an immunological and genetically foreign target in an
immunocompromised organism. It would therefore ap-
pear to remain questionable whether ﬁndings regarding
the recurrence of PSC after OLT are directly transfer-
able to our current understanding of the pathogenesis
of PSC in the pre-transplant patient.
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